5-alpha-reductase inhibitor: Difference between revisions
m Protected "5-alpha-reductase inhibitor": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
'''5α-reductase inhibitors''' (or '''5-alpha-reductase inhibitors''') are a group of [[medication|drugs]] with [[antiandrogen]]ic activity, used in the treatment of [[benign prostatic hyperplasia]] and androgenic (or androgenetic) [[alopecia]]. These drugs decrease the levels of available [[5-alpha reductase|5α-reductase]] prior to testosterone binding with the enzyme, thus reducing levels of [[dihydrotestosterone]] that derives from such a bond. | '''5α-reductase inhibitors''' (or '''5-alpha-reductase inhibitors''') are a group of [[medication|drugs]] with [[antiandrogen]]ic activity, used in the treatment of [[benign prostatic hyperplasia]] and androgenic (or androgenetic) [[alopecia]]. These drugs decrease the levels of available [[5-alpha reductase|5α-reductase]] prior to testosterone binding with the enzyme, thus reducing levels of [[dihydrotestosterone]] that derives from such a bond. | ||
| Line 25: | Line 25: | ||
{{Urologicals}} | {{Urologicals}} | ||
[[Category:5-alpha-reductase inhibitors|*]] | [[Category:5-alpha-reductase inhibitors|*]] | ||
Latest revision as of 19:06, 8 August 2012
5α-reductase inhibitors (or 5-alpha-reductase inhibitors) are a group of drugs with antiandrogenic activity, used in the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia. These drugs decrease the levels of available 5α-reductase prior to testosterone binding with the enzyme, thus reducing levels of dihydrotestosterone that derives from such a bond.
Clinical use
Indications
5α-reductase inhibitors are clinically used in the treatment of conditions which are exacerbated by dihydrotestosterone. Specifically, these indications may include: (Rossi, 2004)
- mild-to-moderate benign prostatic hyperplasia
- androgenic (or androgenetic) alopecia
Adverse drug reactions
Adverse drug reactions (ADRs) experienced with 5α-reductase inhibitors are generally dose-dependent. Common ADRs include impotence, decreased libido, decreased ejaculate volume. Rare ADRs include: breast tenderness and enlargement, and allergic reaction. (Rossi, 2004)
Pharmacology
The enzyme 5α-reductase is involved in the conversion of testosterone to the active form dihydrotestosterone by reducing the Δ4,5 double-bond. In benign prostatic hyperplasia, dihydrotestosterone acts as a potent cellular androgen and promotes prostate growth - inhibiting the enzyme reduces the excessive prostate growth. In alopecia, pattern-baldness is one of the effects of androgenic receptor activation. Reducing the levels of dihydrotestosterone thus reduces alopecia.
Examples
- finasteride (Proscar, Propecia)
- dutasteride (Avodart)
- FCE 28260, an experimental compound
References
- Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2